Efficacy and Safety of Troglitazone for Lipodystrophy Syndromes
Authors: Stephen H. Caldwell
Journal: Annals of Internal Medicine (2001)

Letters15 May 2001Efficacy and Safety of Troglitazone for Lipodystrophy SyndromesStephen H. Caldwell, MDStephen H. Caldwell, MDUniversity of Virginia; Charlottesville, VA 22908-0708 (Caldwell)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-134-10-200105150-00016 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Arioglu and colleagues (1) discussed the association between lipodystrophy and nonalcoholic steatohepatitis (NASH) and the effects of troglitazone. We recently reported on a pilot study of troglitazone for NASH (2) that began before idiosyncratic hepatotoxicity was recognized and troglitazone was withdrawn from the U.S. market.In our study, liver enzyme levels normalized in 7 of 10 patients after 4 to 6 months of troglitazone therapy. This was associated with mild improvement in the histologic score for inflammation on end-of-treatment biopsy samples. However, electron microscopy showed a tendency toward increased mitochondrial morphologic abnormalities, including swelling and development of ...References1. Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman J, et al . Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med. 2000;133:263-74. [PMID: 0010929166] LinkGoogle Scholar2. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol. 2001;96:519-25. [PMID: 0011232700] CrossrefMedlineGoogle Scholar3. Caldwell SH, Swerdlow RH, Khan EM, Iezzoni JC, Hespenheide EE, Parks JK, et al . Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol. 1999;31:430-4. [PMID: 0010488700] CrossrefMedlineGoogle Scholar4. Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl AM. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA. 1999;282:1659-64. [PMID: 0010553793] CrossrefMedlineGoogle Scholar5. Boyer BB, Barnes BM. Molecular and metabolic aspects of mammalian hibernation. Bioscience. 1999;49:713-24. CrossrefGoogle Scholar Author, Article, and Disclosure InformationAffiliations: University of Virginia; Charlottesville, VA 22908-0708 (Caldwell) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoEfficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes Elif Arioglu , Jennifer Duncan-Morin , Nancy Sebring , Kristina I. Rother , Nicole Gottlieb , Jay Lieberman , David Herion , David E. Kleiner , James Reynolds , Ahalya Premkumar , Anne E. Sumner , Jay Hoofnagle , Marc L. Reitman , and Simeon I. Taylor Metrics Cited BySevere insulin resistance syndromesLipodystrophies 15 May 2001Volume 134, Issue 10Page: 1008KeywordsHepatocytesInflammationLipidsLipodystrophyLiverMitochondriaNonalcoholic steatohepatitisOverweightPilot studiesSafety ePublished: 15 May 2001 Issue Published: 15 May 2001 CopyrightCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...